IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Pfizer and Ranbaxy Settle Lipitor Patent Dispute

4:28 PM MDT | June 23, 2008 | Deepti Ramesh

Pfizer (New York) and Ranbaxy Laboratories Ltd. (Gurgaon) say they have settled their patent dispute involving Pfizer’s Lipitor, the largest selling cholesterol-lowering drug worldwide with sales of $12.7 billion. The agreement provides Ranbaxy with a license to sell Atorvastatin, the generic version of Lipitor, in the U.S. starting November 30, 2011, and in Australia, Belgium, Canada, Germany, Italy, the Netherlands, and Sweden starting at various dates, the firms say. The agreement follows unconfirmed media reports earlier this month regarding the...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa